Phathom Pharmaceuticals Q2 EPS $(1.00) Down From $(0.64) YoY

Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly losses of $(1.00) per share. This is a 56.25 percent decrease over losses of $(0.64) per share from the same period last year.

byBenzinga Newsdesk

August 10, 2021

1 minute read

Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly losses of $(1.00) per share. This is a 56.25 percent decrease over losses of $(0.64) per share from the same period last year.

Piper Sandler Maintains Neutral on Cathay General, Lowers Price Target to $46

By Benzinga Newsdesk

Today, 5:39 AM

Piper Sandler analyst Matthew Clark maintains Cathay General (NASDAQ:CATY) with a Neutral and lowers the price target from $47 to $46.

CATY

Here’s How Much You Would Have Made Owning Abiomed Stock In The Last 15 Years

By Benzinga Insights

Today, 5:39 AM

Abiomed (NASDAQ:ABMD) has outperformed the market over the past 15 years by 18.87% on an annualized basis producing…

ABMD

Allakos Announces Initiation Of Phase 2b Clinical Trial Of Subcutaneous Lirentelimab In Chronic Spontaneous Urticaria

By Benzinga Newsdesk

Today, 5:39 AM

Allakos Inc. (NASDAQ:ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today announced it has initiated a Phase 2b clinical trial to

ALLK

Staffing 360 Solutions Expands Its Use Of Artificial Intelligence; Shares Halted On Circuit Breaker To The Upside, Stock Now Up 9.03%

By Happy Mohamed

Today, 5:39 AM

Staffing 360 Solutions, Inc. ((STAF), a company executing an international buy-integrate-build strategy through the acquisition of staffing organizations in the United States and the United Kingdom, announced today the

STAF

Phathom Pharmaceuticals Q2 EPS $(1.00) Down From $(0.64) YoY

Related Posts

Piper Sandler Maintains Neutral on Cathay General, Lowers Price Target to $46

Here’s How Much You Would Have Made Owning Abiomed Stock In The Last 15 Years

Allakos Announces Initiation Of Phase 2b Clinical Trial Of Subcutaneous Lirentelimab In Chronic Spontaneous Urticaria

Staffing 360 Solutions Expands Its Use Of Artificial Intelligence; Shares Halted On Circuit Breaker To The Upside, Stock Now Up 9.03%